ST segment elevation myocardial infarction (STEMI) is commonly induced by thrombus
formation leading to complete occlusion of a major epicardial coronary vessel. We aimed to
explore safety and efficacy of Ivabradine in patients with STEMI associated with left
ventricular dysfunction. 200 consecutive patients with STEMI were included in this
controlled study. All patients had successful reperfusion and LVEF less than 50%. 100
patients received 5 mg ivabradine twice a day in addition to the conventional treatment,
while 100 patients received the conventional treatment only. Composite end point of death,
re-infarction, overt heart failure, or need for revascularization was reported at 30 days.
Ivabradine when added to the conventional treatment reduced the heart rate significantly
compared to the conventional treatment alone. However it did not affect incidence of
primary end point. Ivabradine didn't show a significant impact on major adverse cardiac
events when added to conventional treatment.